drugset / Trial / NCT00114465

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

NCT00114465

Phase 4 Completed 38 enrolled Orphan Australia
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to compare the efficacy of the probiotic VSL#3 versus placebo, in addition to standard maintenance drugs, in maintaining remission in Crohn's disease (CD). The secondary objectives are: * To determine the time till flare of CD patients on VSL#3 compared to placebo. * To assess whether concurrent therapy with VSL#3 leads to an improvement in the quality of life (QOL). * To assess whether concurrent therapy with VSL#3 reduces the severity of a flare if it occurs.

Timeline

Start
2005-06
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VSL#3 Other / unclassified 1 unknown

Indications